На главную
Результаты поиска “Coumadin for atrial fibrillation”
Anticoagulation strategies for Atrial Fibrillation [UndergroundMed]
For more videos, check out our website at: http://videos.undergroundmed.net
Просмотров: 2311 UndergroudMed
New Anticoagulants for Stroke Prevention in Atrial Fibrillation | Christian Ruff, MD
"New Anticoagulants for Stroke Prevention in Atrial Fibrillation" Christian Ruff, MD Treatment Options for Atrial Fibrillation and VTE March 4th, 2013 Brigham and Women's Hospital Boston, MA
Просмотров: 10867 NAThrombosisForum
Atrial Fibrillation: Coumadin to Prevent Stroke
One of the potential devastating consequences of atrial fibrillation is a stroke. You can prevent a stroke with the use of a blood thinner called coumadin. HeartSmartMD co-founder, author and board certified cardiologist Dr. Matt DeVane explains the risks and benefits of using coumadin to prevent strokes in atrial fibrillation. Learn much more at www.HeartSmartMD.com
Просмотров: 641 HeartSmartMD
Perioperative Management of Anticoagulation: 2016 CCS Atrial Fibrillation Guidelines
Perioperative Management of Anticoagulation in Patients with AF 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Featuring: L. Brent Mitchell, MD Libin Cardiovascular Institute of Alberta University of Calgary, and Alberta Health Services
Просмотров: 1968 Canadian Cardiovascular Society
Natural 'Blood thinners' for Afib
This video is about Natural 'Blood thinners' for Afib. In this video, i talk about some natural blood thinners like Garlic, Ginger, Nattokwinase, Hawthorn, Motherwort etc and why i would not recommend them as an alternative to warfarin or the NOACs in patients with Afib
Просмотров: 25661 York Cardiology
Atrial Fibrillation, Coumadin®, & the CHADS2 Score--StopAfib.org interviews Dr. Manish Shah
http://www.stopafib.org If you have atrial fibrillation, how do you know your risk of stroke and whether or not you should be taking Coumadin® or warfarin? Dr. Manish Shah talks about the CHADS2 scoring system that addresses this afib controversy and how your doctor will assess your CHADS2 score. Dr. Shah is an electrophysiologist, Associate Director of Cardiac Arrhythmia Research at the Washington Hospital Center in Washington, D.C., and Assistant Professor of Medicine at Georgetown University School of Medicine. StopAfib.org, at http://www.StopAfib.org, is for atrial fibrillation patients by afib patients. A full video transcript can be found at: http://stopafib.org/newsitem.cfm/NEWSID/135
Просмотров: 5753 StopAfib
AFib, anticoagulants and antidotes
In this video, Dr Sanjay Gupta, discusses the role of different anticoagulants in atrial fibrillation and why the lack of antidotes shouls not put anyone off using the NOACS.
Просмотров: 1555 York Cardiology
Atrial fibrillation: 2 key managment issues explained
In this video we try to explain two of the key issues for the management of atrial fibrillation. 1.The first issue is the issue of heart rate control versus heart rhythm control. Will your physician try to just control your heart rate or try to flip your rhythm back in to sinus rhythm from atrial fibrillation? With heart rate control our goal is to try to control the heart rate only. Thus the patient could still be in atrial fibrillation however heart rate is brought under control (60-110 bpm) with medications like beta blockers- metoprolol and calcium channel blockers like diltiazem etc. By rhythm control the physician tries to reset the heart into into sinus rhythm from atrial fibrillation. This can be done with the help of medications and is called as chemical cardioversion. Or it can be done by electrical shock also known as electrical cardioversion. Medications that can be used to keep the patient in the rhythm. These medications include, flecanide, sotalol or amiodarone etc. 2. The second key issue in the management of atrial fibrillation is prevention of stroke. Stroke is a deadly complication of atrial fibrillation. The first question that arises is what is the risk of stroke in a given patient with atrial fibrillation. A patients risk of stroke can be calculated by using an abbreviation called CHAD2VASC2 (explained in the table). Blood thinners (like Coumadin or newer agents like xeralto/apixaban/rivaroxaban) are recommended for patients with a score more than 2. For a score of zero usually no blood are recommended and for patients with the score of one either blood thinner or are aspirin as recommended. If you like this video and would like to see more of such patient educational videos go to our website www.patienteducationpro.com.
Просмотров: 1623 PatientEducationPro
8 atrial fibrillation Management
Просмотров: 17814 drsarmaji
Bridging Anticoagulation
ISTH 2015 - Thomas Ortel, Chief, Division of Hematology, Professor of Medicine and Hematology and Medical Director, Clinical Coagulation Laboratory, Duke University Medical Center - The management of patients with atrial fibrillation on warfarin who need treatment interruption for surgery/procedure is a common clinical problem. Bridging with low-molecular-weight heparin has been used to minimize the time that patients are not anticoagulated to mitigate the risk for arterial thromboembolism. This study seeks to determine the efficacy and safety of bridging anticoagulation.
Просмотров: 2673 Thrombosis.TV
Managing atrial fibrillation: Anticoagulation, ablation, and improving quality of life
In a video originally posted on TheHeart.org, Win-Kuang Shen, MD, sits down with Samuel J Asirvatham, MD, and Douglas Packer, MD, for an in-depth discussion of the major issues involved in managing atrial fibrillation, from increasing patient awareness to stroke prevention and when and how to use ablation.
Просмотров: 761 Mayo Clinic
Coumadin (Warfarin): Clinical Pharmacist Explains Everything You Should Know
Dr. Jacqueline DiMarco, clinical pharmacist, explains everything patients should know about the blood thinner Coumadin (warfarin). We cover the mechanism of action against vitamin K, the conditions it treats (including atrial fibrillation and deep vein thrombosis a.k.a DVT), the INR and how it should be monitored, as well as the Lovenox bridge and dietary recommendations. Make sure to check us out on the web at http://www.DoctorVoices.com for the most dependable health information on the internet. This video and all content produced by Doctor Voices is for educational purposes only, please make sure to follow with your doctor for all of your health conditions. Please see our terms of use on our site.
Просмотров: 33872 Doctor Voices
NOACs should replace warfarin in all patients with atrial fibrillation - Pro - J. Camm
This video was recorded during the ESC Heart & Brain workshop course held at Charles University in Prague, Czech Republic. The goal of this first edition of this workshop was to bring together leading experts in the field of stroke and cardiologists, neurologists, radiologists, surgeons and other specialists to learn from each other. Find out more about the ESC Council on Stroke: https://www.escardio.org/Councils/Council-on-Stroke?hit=youtube
Просмотров: 191 European Society of Cardiology
How does warfarin help if I have atrial fibrillation?
Specialist Dr John Worthington talks about the anticoagulant medicine warfarin, including how it reduces the risk of stroke in people with atrial fibrillation. Find out more about warfarin at http://www.nps.org.au/warfarin
Просмотров: 677 NPS MedicineWise
Anticoagulation and risk of bleeding with Atrial Fibrillation
Eric Prystowsky, MD explains important points to keep in mind when weighing the risk of stroke and bleeding risk with anticoagulation for AFib patients.
Просмотров: 113 American Heart Association
Atrial Fibrillation in Older Adults: Anticoagulation
November 18th, 2016 Michael A. Chen, MD, PhD Associate Professor of Medicine Division of Cardiology Harborview Medical Center University of Washington
Просмотров: 113 NW GWEC
6/16/17: Atrial Fibrillation: Can We Organize the Chaos?
Anne O'Connor, MD and Jennifer Wright, MD co-present a lecture about clinical management of atrial fibrillation. Dr. O'Connor is an Associate Professor (CHS) whose clinical interests include critical cardiology, reducing readmissions for heart failure and acute myocardial infarct patients, and cardiovascular imaging. Dr. Wright is a Clinical Assistant Professor who specializes in cardiology and electrophysiology. Both are members of the Division of Cardiovascular Medicine in the Department of Medicine at UW-Madison. The title of their June 16, 2017 Grand Rounds talk is "Atrial Fibrillation: Can We Organize the Chaos?" University of Wisconsin Department of Medicine Grand Rounds are presented throughout the academic year and are intended for health care professionals and medical researchers. Unless otherwise indicated, Grand Rounds occurs in the William S. Middleton Memorial Veterans Hospital auditorium, Room A1028, Madison, Wisconsin. All faculty and staff are invited and encouraged to attend. For more information on the Grand Rounds lecture series, visit http://www.medicine.wisc.edu/dom/medicine-grand-rounds
Просмотров: 2392 UW Department of Medicine
Atrial Fibrillation & Coumadin® Replacements--StopAfib.org interviews Dr. Manish Shah
http://www.stopafib.org Dr. Manish Shah talks about Dabigatran and Rivaroxaban, new drugs in clinicals trials to replace the blood thinner Coumadin® (warfarin), an anticoagulant frequently used to avoid strokes by those with atrial fibrillation. He talks about the two categories of these new drugs, thrombin inhibitors and Factor Xa (10a) inhibitors. Dr. Shah is Associate Director of Cardiac Arrhythmia Research at the Washington Hospital Center in Washington, D.C., and Assistant Professor of Medicine at Georgetown University School of Medicine. StopAfib.org, at http://www.StopAfib.org, is for atrial fibrillation patients by afib patients. A full video transcript can be found at: http://stopafib.org/newsitem.cfm/NEWSID/135
Просмотров: 4893 StopAfib
Eliquis: New Medication for Atrial Fibrillation
An in-depth conversation between Pentucket Medical cardiologists Seth Bilazarian and Sunny Srivastava, focusing on a newly released medicine to reduce the risks of atrial fibrillation. The latest among recently approved blood thinners, Eliquis joins Pradaxa and Xarelto as an alternative to Coumadin, a drug that has been in use since the 1950s. Like Pradaxa and Xarelto, Eliquis has been shown to reduce risk of stroke and bleeding, as well as mortality. All the new drugs eliminate the need for regular blood testing that Coumadin necessitates.
Просмотров: 28864 PentucketMedical
Warfarin Anticoagulation, Dementia, and Atrial Fibrillation
DescriptioDr. Malini Madhavan, an Assistant Professor of Cardiology at Mayo Clinic in Rochester, MN, discusses her article appearing in the February 2018 issue of Mayo Clinic Proceedings which examined the effect of anticoagulation in patients experiencing atrial fibrillation and its relationship to dementia. She found significant reductions in the incidence of dementia in those patients maintaining therapeutic levels of warfarin. She notes further studies are needed for the effects of newer anticoagulants. Available at: https://tinyurl.com/ycjvxykkn
Просмотров: 49 Mayo Proceedings
Comparing Eliquis to Warfarin In Atrial Fibrillation Patients
While warfarin has long been a common treatment option for patients with atrial fibrillation new medications are coming to the market which provide different benefits than the original option.
Просмотров: 3482 MD Magazine
Session 7: Atrial fibrillation in the ED - Can We Do More? (Cardioversion, Anticoagulation)
Speaker: A/Prof Ching Chi Keong Date: 28th February 2016
Просмотров: 134 SEMSingapore
Goals of treating atrial fibrillation. Rhythm vs rate control and anticoagulation.
Description of goals of treating atrial fibrillation. Rhythm vs rate control and anticoagulation.
Просмотров: 803 Diego Belardi
EmpoweRN.com Hi Guys! I really hope this video helps you out a ton! This medication is one of the major ones you will see in adult Med Surg & Critical care. Although it saves lives, we have to be very careful when taking care of patients with clotting tendencies. Furthermore, we must also educate our patients about diet restrictions, safety precautions and the importance of their follow up appointments. I hope this video simplifies at least a little bit of it ;) Also, remember... you can access the audio of the video to download on your device, so that not matter where you are, you can always be learning. If you prefer to watch the video without any music, you can go to my website... you will also find the audio there: http://wp.me/s4CVjD-coumadin I hope this & all of the videos help you tremendously. Much love, - Caroline Warfarin aka Coumadin is the most used oral anticoagulant in the world and has been used for more than 50 years for therapy in prevention of thrombus formation and subsequent thromboembolic events. Anticoagulants are blood thinners which prevent formation of blood clots as well as prevent existent blood clots from increasing in size. Blood clots can hinder blood circulation and lead to serious medical conditions, like stroke, heart attack and pulmonary embolism. Thus warfarin is helpful in treating and preventing vein and artery blockage, stroke and heart attack. Mechanism of Action Warfarin slows down the formation of blood clots within 24 hours, but the complete effect takes place between 72 to 96 hours after taking the medication. Blood clot formation is a complicated process which requires certain compounds known as coagulating factors to be present. These coagulating factors are produced by the liver. In the presence of sufficient vitamin K. Warfarin acts by inhibiting the presence of vitamin K and this inhibits the formation of coagulating factors. Substances that require vitamin K for their formation are: the anticoagulant proteins C and S and factors II, VII, IX, and X. Therefore, medications like warfarin block coagulating factors and disturb the process of clot formation. Thus slowing down blood clot formation. In the case of blood clots that are already formed, warfarin stops the clot from getting bigger. It also prevents breakage of the clot which can be otherwise dangerous if it travels in the bloodstream and blocks blood vessels. Warfarin cannot destroy or dissolve a blood clot that is already there. But the blood clot itself may slowly dissolve with time. Nor can Warfarin reverse ischemic tissue damage either, but, may help avoid secondary thromboembolic complications that can be dangerous and even fatal. Indication Warfarin (Coumadin) is indicated for/to: • Prophylaxis, pulmonary embolism (PE), venous thrombosis and its extension, and to prevent blood clots from moving to other parts of the body. • Reduce the risk of another stroke or heart attack in clients who already have had stroke or heart attack, and to reduce the risk of death. • Prevent and treat blood clots associated with atrial fibrillation (irregular rapid heartbeat), heart-valve replacement and blood clots in lungs and legs.
Просмотров: 22420 EmpoweRN
Can I take an aspirin for atrial fibrillation?
Join our channel by subscribing here. If you have enjoyed our video, please like it and leave a comment about what other videos you may be interested in. Your help in creating great, relevant content is greatly appreciated. Although it was thought for many years that aspirin was sufficient to 'thin' your blood to prevent blood clots inside the heart from forming, the latest evidence is that aspirin is just not effective enough in people who have atrial fibrillation associated with other risk factors, including being elderly! This video describes the role of aspirin in managing patients with atrial fibrillation. Transcript: Thank you for visiting Doctor AFib, I'm Dr. Morales. In today's video segment we're going to be talking about the role of aspirin when it comes to managing atrial fibrillation. In a previous video segment, I discussed your risk of stroke with atrial fibrillation as defined by the CHADSVASc risk score. Most people who have atrial fibrillation are going to have a CHADSVASc score of two or greater and it's going to be recommended to take stronger blood thinners, something called anticoagulation. However, when I explain it to the patients, probably the next question is: what about an aspirin? Can I take an aspirin for atrial fibrillation? So, let's look at the data regarding aspirin for atrial fibrillation. Aspirin has been studied for atrial fibrillation since the late 80s and early 90s and in multiple clinical trials. Back in 2007, there was a meta-analysis which combined the results of several studies and showed that aspirin provides a reduction in the rate of stroke by about 22%. Most studies in the 80s and 90s used aspirin 325 milligrams daily. A later study called the Active W trial looked at the combination of aspirin together with Plavix and that reduced your risk of stroke by about 44%. However, in that same meta-analysis in 2007, it showed that Warfarin, also called Coumadin, reduced risk of stroke in atrial fibrillation by about 66%. Several studies were done back in the late 80s or 90s early 2000s looking at comparing aspirin with Warfarin and every time Warfarin was found to be superior to aspirin for reducing your risk of stroke. As a result, for many years Warfarin became the standard of care for reducing the risk of stroke because it was far better in terms of the reduction amount for reducing the risk of stroke. Fortunately, these days there are other options, where newer blood thinners have come out as an alternative to Warfarin. Listen to the video for more Read my blog posts at http://www.DrAFib.com
Просмотров: 339 Dr. AFib
Atrial fibrillation -- achieving safer anticoagulation
Sunil Rao John Alexander
Просмотров: 147 Duke Clinical Research Institute
Atrial Fibrillation: Symptoms Treatment Medications
Dr. Alo discusses atrial fibrillation treatment algorithms including many of the newer rate and rhythm control drugs. Also discusses the novel anticoagulation options. Target audience is informed patients and medical professionals. hhtp://MohammedAlo.com
Просмотров: 10869 Mohammed Alo
Treatment Guidelines for Atrial Fibrillation, AF Patients
Treatment Guidelines for Atrial Fibrillation, AF Patients: Current ESC Guidelines for patients with atrial fibrillation explicitly recommend an oral anticoagulant for patients with two additional risk factors. And in patients with one additional risk factor an oral anticoagulant is recommended in preference to aspirin. Yet only half of all patients who need an anticoagulant, as defined by guidelines, actually receive one. Not surprisingly, it turns out that only one in ten people with AF who suffer a stroke were receiving adequate anticoagulant protection at the time. References: Gladstone DJ, B ui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-240. Waldo AL, Becker RC, Tapson VF, et al; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729-1736. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360-1420.
Просмотров: 16662 Thrombosis Adviser
Developing anticoagulation management and therapy for atrial fibrillation through primary care
Atrial fibrillation is the commonest heart rhythm abnormality, substantially raising risk of stroke and death and affecting around 8.8 million people in the EU, with up to 2% of the UK population taking oral anticoagulation medication. Birmingham research has supported a move from lab blood tests and secondary care to primary care and more recently patient self-management through development of new testing and management approaches, which have helped improve clinical outcomes. Clinical trials led in Birmingham have also proven the safety of anticoagulation therapy in elderly patients, and led to the establishment of the National Centre for Anticoagulation Training within the University, which provides accredited training for health care professionals involved in the management of patients.
Просмотров: 195 University of Birmingham
Warfarin, Diet and Atrial Fibrillation
James Edgerton, MD discusses diet changes and warfarin with an atrial fibrillation patient. Learn more about AFib patient education at MyAFibExperience.org
Просмотров: 255 American Heart Association
9 atrial fibrillation Anticoagulation
Просмотров: 1263 drsarmaji
Top Developments in Anticoagulant - Anticoagulation in AF  (Heart&Stroke Clinical Update)
Heart & Stroke Clinical Update 2015 www.heartandstroke.ca/clinicalupdate Plenary 3c Top Developments in Anticoagulant - Oral Anticoagulation for AF-related Stroke Prevention Presented by: Andrew Ha, MD, FRCPC (see below) Hilton Toronto, December 2015 Learning Objectives 1. Review common stroke and bleeding assessment schema for patients with atrial fibrillation (AF). 2. Review randomozed controlled trials comparing the efficacy and safety of warfarin versus noval oral anticoagulants (NOAC). 3. Discussion of “real-world” observational studies on the use of warfarin and NOAC agents. 4. Review the safety and effectiveness of oral anticoagulation in high-risk patient subgroups (e.g. chronic kidney disease). 5. Reversal agents for NOACs Session Description Stroke prevention with oral anticoagulation (OAC) is one of the most important treatment goals in the management of patients with atrial fibrillation (AF). Traditionally, warfarin is the drug of choice for AF-related stroke prevention. Recently, the introduction of novel oral anticoagulant (NOAC) agents has revolutionized this field. As a consequence of the rapid uptake of NOAC agents in clinical practice, health practitioners now face many new questions when prescribing OAC for AF patients with elevated stroke risk. For instance, there is a pressing need to develop a greater understanding of the “real-world” effectiveness and safety between warfarin and NOAC agents. In addition, further delineation of the risks and benefits of warfarin vs. NOAC agents in high-risk AF patient subgroups (e.g. elderly, patients with kidney disease, patients treated with antiplatelet therapy) will be most welcomed. In this session, we will examine data from randomized clinical trials, “real-world” registries, and large-scale health administrative databases to address these keys questions on OAC use for AF-related stroke prevention. Andrew Ha, MD, FRCPC Staff cardiac electrophysiologist, Toronto General Hospital, University Health Network The following information was provided by speakers at the Clinical Update 2015. The information is intended for use by healthcare professionals for reference and education only and is not intended to be a substitute for a physician's advice, diagnosis or treatment. You should consult your physician for personal health matters.
Просмотров: 1542 Heart and Stroke
AFib: Anticoagulation Strategies - Dallas CVI 2015
Dr. Owen Obel discusses new treatments for atrial fibrillation
Просмотров: 413 Manos Brilakis
Exercise "Dose" and Anticoagulation for AFib
Dr. Christopher Cannon discusses articles appearing this week in Circulation, AJC, and in NEJM on exercise "dose" and on anticoagulation for Afib. Christopher P. Cannon, MD, FACC Statements or opinions expressed in this program reflects the views of the contributors and do not reflect the official policy of the ACCF, unless otherwise noted.
Просмотров: 648 American College of Cardiology
The two types of Afib
Type 1 and type 2 AF Most medical conditions in the western world are caused by one or more of the following conditions: Age Genetics Luck and Lifestyle. Lets look at diabetes. There is type 1 diabetes which is usually caused by bad genetics or just bad luck and affects young patients and there is type 2 diabetes which affects older patient and is usually caused by age and lifestyle. They are managed differently. Type 1 diabetes is treated with Insulin Type 2 diabetes is treated with tablets/diet and sometimes insulin (and lifestyle changes) In the same way, i believe that there are 2 types of Afib and they are caused by different things but unfortunately they are thought of as one condition and therefore all Afib is managed in the same way but ideally they should be managed differently and if you understand the difference, it may allow you to target those treatments which will give you most benefit. Type 1 Afib. Whilst most patients with Afib is seen in older patients with comorbidities, we do see it in younger patients who have no comorbidites…this has historically been termed lone Afib. In these patients, the reason of Afib is usually genetic or bad luck when you scan these patients they have normal sized left atria and often their Afib comes and goes and interestingly they seem to really not tolerate their Afib very well at all. When you follow them up, they have an exceptionally good prognosis with no increase in stroke risk and these patients seem to respond extremely well to ablation. Type 2 Afib, Older patients with Afib usually tend to develop it because of increased age and bad lifestyle. They often have comorbidites such as diabetes, hypertension, sleep apnoea and vascular disease. Interestingly when you scan their hearts they have big sized left atria and they seem to tolerate their Afib very well. Often many are found to be in Afib incidentally and they are often in persistent Afib. When you follow them up, they do very badly in the short to medium term and have a much higher incidence of strokes, heart failure and even sudden death and therefore need anticoagulation. Often they don’t respond as well to ablation and even if they do they often end up requiring more than one procedure and taking away the Afib does not alter their risk of strokes or overall prognosis. and therefore I think that patients with type 1 Afib should be treated with reassurance and ablation and patients with type 2 A fib do better with anticoagulation and lifestyle modification and ablation in the case of refractory symptoms
Просмотров: 6863 York Cardiology
Atrial Fibrillation Anticoagulation - PowerPoint Presentation
http://www.medicaldump.com - Please visit the site for FREE medical PowerPoints, medical PowerPoint templates, medical e-books related to all specialties including ophthalmology, cardiology, neurology, nephrology, GI, etc. This is a Cardiology PowerPoint presentation about Atrial Fibrillation Anticoagulation.
Просмотров: 660 medicaldump
Warfarin versus the NOACs for the treatment of atrial fibrillation
3% of the population suffers from AF. Most such patients need blood thinning medication. Usually such patients are prescribed warfarin but now there are alternative agents termed the NOACS (Novel oral anticoagulants). There is still a reluctance to prescribe such agents based on lack of knowledge and high perceived costs. In this video, i give an honest account of use of NOACs in the management of AF
Просмотров: 2288 York Cardiology
Afib Symptoms And Treatment   What Is The Best Afib Treatment
http://www.herbscellnutrition.com/home/angirx-detorex-combo/ Afib Symptoms And Treatment - What Is The Best Afib Treatment? Many people with atrial fibrillation or those who are undergoing certain treatments for atrial fibrillation are at especially high risk of blood clots that can lead to stroke. The risk is even higher if other heart disease is present along with atrial fibrillation. Your doctor may prescribe blood-thinning medications (anticoagulants) such as: Warfarin (Coumadin, Jantoven). Warfarin may be prescribed to prevent blood clots. If you're prescribed warfarin, carefully follow your doctor's instructions. Warfarin is a powerful medication that may cause dangerous bleeding. You'll need to have regular blood tests to monitor warfarin's effects. Newer anticoagulants. Several newer blood-thinning medications (anticoagulants) are available. These medications are shorter acting than warfarin and don't require monitoring. Also, these medications are not approved for people who have mechanical heart valves. It's very important to take these medications exactly as prescribed. Dabigatran (Pradaxa) is an anticoagulant medication that's as effective as warfarin at preventing blood clots that can lead to strokes, and doesn't require blood tests to make sure you're getting the proper dose. Many people have spells of atrial fibrillation and don't even know it so you may need lifelong anticoagulants even after your rhythm has been restored to normal.
Просмотров: 21 herbe maan
Reducing stroke risk in atrial fibrillation
Atrial fibrillation (AF) increases stroke risk five-fold. This video explains how this risk could be reduced through appropriate anticoagulation. It features Arrhythmia Alliance and AF Association CEO, Trudie Lobban MBE, AF Association Deputy CEO, Jo Jerrome, leading heart rhythm specialist, Professor John Camm and CEO of Anticoagulation Europe, Eve Knight. Developed in association with Boehringer Ingelheim.
Просмотров: 2288 ArrhythmiaAlliance
Weighing Your Options – Anticoagulation Therapy
Watch this short video to learn more about the benefits and risks of anticoagulants, a common medication for those diagnosed with AFib.
Просмотров: 1817 National Stroke Association
Complete Guide To Atrial Fibrillation: Causes, risks of stroke, medication, symptoms and treatments
Reviews what is atrial fibrillation (afib), how common is afib, what causes afib, how afib causes stroke, what is the risk of stroke with afib, how to calculate your risk of stroke with afib, how to reduce chances of stroke with atrial fibrillation, what is coumadin, what are the risks of coumadin, what are the new anticoagulants available in the market today to treat afib, occlusion devices, when is an occlusion device indicated, the Watchman device, the Lariat Device, what are the symptoms of afib, medications for afib symptoms including amiodarone, the risks of amiodarone, risks and benefits of antiarrhythmics, what is an afib ablation, how are atrial fibrillation ablations done, what is the benefit of an afib abaltion. Written by two cardiologists: Dr. Jorge Romero MD FACC FHRS, electrophysiologist, and Dr. José Taveras MD FACC. Produced by Doctablet. You can find the post for this video at: https://doctablet.com/medicine/cardiology/arrhythmina/afib/afib-series/ Please visit Doctablet for more topics that will supplement the information you see in this video: https://doctablet.com/ Also! You can ask questions related to this topic, we enjoy answering questions, it helps us get feedback and gives us material for future videos. ALSO!, most important! Subscribe to our YouTube Channel! It means the world to https://www.youtube.com/channel/UCiGhz8d21xvPWs7FgLx2sMFA/?sub_confirmation=1
Просмотров: 427 Doctablet
Anticoagulation Choice - Demo
A video demonstration of shared decision making about anticoagulation in atrial fibrillation using the Anticoagulation Choice conversation aid. For more information, visit http://www.mayo.edu/research/labs/knowledge-evaluation-research-unit/overview?mc_id=us&utm_source=youtube&utm_medium=sm&utm_content=video&utm_campaign=mayoclinic&geo=national&placementsite=enterprise&cauid=100504
Просмотров: 238 Mayo Clinic
Focal atrial tachycardia originating at coumadin ridge of the left atrium.
A focal atrial tachycardia that led to atrial fibrillation. This is the left atrial electroanatomical map of a 56-year-old male with persistent atrial fibrillation who had failed electrical cardioversion and antiarrhythmics. Following circumferential ablation around the left and right pulmonary veins (red ball markers), a focal atrial tachycardia remained. It was localized between the left atrial appendage and the left superior pulmonary vein. Radiofrequency ablation using a Biosense Webster ThermoCool® catheter at this location terminated the arrhythmia. This activation map of the left atrium and the ablation focus was created using Biosense Webster's Carto®3 system. The map was initially created at an earlier time using a cardiac computed tomography (CT). During the procedure the electroanatomic structure was created with the catheter as it touched the heart walls and merged with the CT scan to provide a GPS-environment to guide ablation treatment. The total time of this case was more than 4 hours, delayed by this persistent atrial tachycardia which we initially thought was an atypical atrial flutter created from our initial ablation lines. The red-on-blue color shows the electrical depolarization from the ectopic atrial focus originating at the coumadin ridge, and then following it as a function of time, as it sweeps across the left atrium. The follow-up map shows the origination of that ectopic signal. The earliest time is shown in red color, the latest in magenta. The red ball-markers are ablation points that were performed earlier in the study. In addition to the circumferential ablations, a roof-line was performed. Obviously, the initial ablation procedure was unable to "cure" the patient, requiring subsequent mapping. The cycle length of this atrial tachycardia is 250 msec, and persisted for about 2 hours while this map was created.
Просмотров: 1153 wwhitwam
Atrial Fibrillation & Stroke Prediction--StopAfib.org interviews Prof. Gregory Lip
http://www.stopafib.org StopAfib.org interviews Prof. Gregory Lip, of the University of Birmingham (UK) Find more information on the CHADS2 scoring system, and on Prof. Lip, at: http://www.stopafib.org/newsitem.cfm/NEWSID/369 In this video interview, Dr. Lip discussed the CHA2DS2-VASc tool, which was recently adopted by the European Society of Cardiology Atrial Fibrillation Guidelines for predicting stroke risk in atrial fibrillation. The CHA2DS2-VASc tool is especially useful for predicting which patients are truly low risk and do not need to be on anticoagulants, and which patients are not low risk and thus should be on anticoagulants such as warfarin (Coumadin) or the newer drugs. The CHA2DS2-VASc tool identifies additional risk factors that were left out of the CHADS2 scoring tool, including being female, age 65-74, or having vascular (heart) disease. Dr. Lip is a Professor of Medicine at the University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Просмотров: 2541 StopAfib
Stroke Prevention in Atrial Fibrillation
The stroke prevention webcast highlights assessing the risk of stroke for all patients with atrial fibrillation, as well as the pharmacologic stroke prevention techniques and anticoagulation options. Visit http://www.ccfcme.org/strokevgrvideo to claim CME credit or learn more about the Stroke Virtual Grand Rounds series. The case-based stroke prevention webcast features expert faculty member, Dr. David Garcia, of University of Washington, and commentary by Activity Director, Dr. Edward Manno. The video was produced by the Cleveland Clinic Foundation Center for Continuing Education and the Cleveland Clinic Cerebrovascular Center. Interested in related CME education? Visit http://www.clevelandclinicmeded.com/specialties/Neurology.aspx?id=133&name=Neurology
Просмотров: 745 ClevelandClinicCME
Dr Foran explains an alternative to anticoagulation treatment
Dr John Foran is a consultant cardiologist. He explains why atrial fibrillation patients are more likely to suffer a stroke as a result of blood clots. Patients are often prescribed with anti-coagulation treatment like warfarin. Now, an alternative treatment called left atrial appendage closure is available. Dr Foran explains the procedure. This video has been produced by Watchman.
Просмотров: 2991 ArrhythmiaAlliance
What are my options for anticoagulation therapy for Atrial Fibrillation?
Mintu Turakhia, MD, MAS, discusses the difference in oral anticoagulants and anticoagulation therapy that includes a clinic or coach. To connect with other patients visit: http://spr.ly/60598YnMv
Просмотров: 134 American Heart Association